Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years

AIDS

Volumn 12, Issue 7, 1998, Pages 697-704

  Arnó, Albert ^a   Ruiz, Lydia ^a   Juan, Manuel ^a   Zayat, Moh'D Khalil ^a   Puig, Teresa ^a   Balagué, Montserrat ^a   Romeu, Joan ^a   Pujol, Ricardo ^a   O'Brien, William A ^b   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Antiretroviral treatment; CD28 antigen; CD4+ T lymphocyte; CD45 antigen; CD8+ T lymphocyte; Immune restoration; Surface marker; T cell receptor V repertoire; Undetectable plasma HIV 1 RNA

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE SURFACE MARKER; T LYMPHOCYTE RECEPTOR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RETROSPECTIVE STUDIES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 7144242308     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199807000-00005     Document Type: Article

References (26)

1. Lang W, Perkins H, Royce R, Jewell N, Winkelstein W Jr: Pattern of T lymphocyte changes with human immunodeficiency virus infection from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989, 2:639-642.
2. Connors M, Kovacs A Krevat S, et al.: HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire which are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
3. Chou CC, Gudernan V, O'Rourke S, et al.: Phenotypically defined memory CD4+ cells are not selectively decreased in chronic HIV disease. J Acquir Immune Defic Syndr 1994, 7:665-675.
4. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D: Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science 1991, 254:860-862.
5. De Martini RM, Turner RR, Formanti SC, et al.: Peripheral blood mononuclear cell abnormalities and their relationship to clinical course in homosexual men with HIV infection. Clin Immunol Immunopathol 1988, 46:358-271.
6. Giorgi JV, Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989, 52:10-18.
7. Roederer M, Dubs JG, Anerson MT, Raju PA, Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995, 95:2061-2066.
8. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
9. Kelleher A, Bloch M, Smith D, et al.: Reversal of CD8 activation in patients with primary HIV infection treated with AZT, 3TC and indinavir. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1139].
10. Pino-Otin MR, Juan M, de la Fuente MA, et al.: CD50 (intercellular adhesion molecule-3) expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets. Tissue Antigens 1995, 46:32-44.
11. Schockmel GA, Yerly S, Perrin L: Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997,14:179-183.
12. Rowell JG, Walkers DE: Analyzing data with repeated observations on each experimental unit. J Agricultural Sci 1976, 57:423-432.
13. Carr A, Emery S, Kelleher A, Law M, Cooper DA: CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr 1996, 13:320-326.
14. Mahalingam M, Peakman M, Davies ET, Pozniak A, McManus TJ, Vergani D: T cell activation and disease severity in HIV infection. Clin Exp Immunol 1993, 93:337-343.
15. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
16. Ramilo O, Bell KD, Uhr JW, Vitetta ES: Role of CD25+ and CD25- T cells in acute HIV infection in vitro. J Immunol 1993, 150:5202-5208.
17. Borvak J, Chou CS, Bell H, et al.: Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J Immunol 1995, 155:3196-3204.
18. Peakman M, Mahalingam M, Pozniak A, McManus TJ, Phillips AN, Vergani D: Markers of immune cell activation and disease progression. Adv Exp Med Biol 1995, 374:17-26.
19. Kestens L, Vanham C, Vereecken C, et al.: Selective increase of activation antigens HLA-DR and CD38 on CD4+CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994, 95:436-441.
20. Bofill M, Mocroft A, Lipman M, et al.: Increased number of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996, 10:827-834.
21. Lane HC, Deppert WC, Greene G, Whaler G, Waldmann TA, Fauci A: Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985, 313:79-84.
22. Landay AL, Mackewicz C, Levy JA: An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993, 69:106-116.
23. Fiorentino S, Dalod M, Olive D, Guillet JG, Gomard E: Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol 1996, 70:2022-2026.
24. Saukkonen JJ, Kornfeld H, Berman JS: Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients. J Acquir Immune Defic Syndr 1993, 6:1194-1204.
25. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 400 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335:1091-1098.
26. Delta Coordinating Commiftee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.